QUESTION 15
GS3
15 marks
Why is there so much activity in the field of biotechnology in our country? How has this activity benefitted the field of biopharma?
WRITE IN
11 min
250 words
What the examiner wants
Explain why biotechnology activity is rising in India and how biopharma has gained.
ExplainMake clear how and why it happens: causes, process, and an example for each point.
Demand-wise check
- 1Drivers: skilled scientists, low cost, DBT and BIRAC funding, startups, pharma base, policy support≈50 words
- 2Biopharma gains: vaccines at scale, biosimilars, diagnostics, generic biologics≈50 words
- 3Examples: Rotavac, Covaxin, ZyCoV-D, low-cost insulin and monoclonal antibodies≈50 words
- 4Constraints: R&D spending, regulation speed, IPR, clinical trial capacity≈50 words
Open in about 30 words and close in about 30.
Answer plan
Reasons for activitySpecific biopharma outcomesChallengesSteps (BioE3, Biopharma Mission)Conclusion
Where marks usually go
- Listing biotech applications in agriculture or environment, not biopharma
- No Indian product examples
Draw this
- Timeline: DBT 1986 → BIRAC 2012 → Biopharma Mission 2017 → Covaxin 2021 → BioE3 2024
Value addition
- SchemeNational Biopharma Mission (2017), co-funded with the World Bank, supports biopharma product development.DBT and BIRAC
- ExampleZyCoV-D (2021) was the world's first DNA vaccine approved for humans.DBT / Zydus
- PolicyBioE3 policy (August 2024) aims at high-performance biomanufacturing.Union Cabinet, 2024
Mapped topper copies
Reviewed public-source references related to this PYQ. Same-syllabus references are labelled separately.
- Shakti Dubey · AIR 1 · Page 13 ↗Reviewed PYQ reference
- Aniket Ranjan · AIR 48 · Page 38 ↗Same syllabus reference
- Mayank Purohit · AIR 33 · Page 9 ↗Same syllabus reference
- Aniket Ranjan · AIR 48 · Page 11 ↗Same syllabus reference
Links open original public sources. MainsBuddy does not host these answer sheets.
Next: plan for one minute, write it in 11 minutes, then get it checked.